Obstructive Hypertrophic Cardiomyopathy Clinical Trials

5 recruitingLast updated: May 5, 2026

There are 15 actively recruiting obstructive hypertrophic cardiomyopathy clinical trials across 29 countries. Studies span Phase 2, Phase 3, Phase 4. Top locations include Los Angeles, California, United States, San Francisco, California, United States, Boston, Massachusetts, United States. Updated daily from ClinicalTrials.gov.


Obstructive Hypertrophic Cardiomyopathy Trials at a Glance

15 actively recruiting trials for obstructive hypertrophic cardiomyopathy are listed on ClinicalTrialsFinder across 6 cities in 29 countries. The largest study group is Phase 2 with 4 trials, with the heaviest enrollment activity in Los Angeles, San Francisco, and Boston. Lead sponsors running obstructive hypertrophic cardiomyopathy studies include Bristol-Myers Squibb, Shandong Suncadia Medicine Co., Ltd., and Cytokinetics.

Browse obstructive hypertrophic cardiomyopathy trials by phase

Treatments under study

About Obstructive Hypertrophic Cardiomyopathy Clinical Trials

Looking for clinical trials for Obstructive Hypertrophic Cardiomyopathy? There are currently 5 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Obstructive Hypertrophic Cardiomyopathy trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Obstructive Hypertrophic Cardiomyopathy clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 115 of 15 trials

Recruiting
Phase 2

A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy

Non-obstructive Hypertrophic Cardiomyopathy
Imbria Pharmaceuticals, Inc.165 enrolled56 locationsNCT07023614
Recruiting

Mavacamten Outcomes in Hypertrophic Cardiomyopathy (HCM) and the Associated Patient and Physician Experiences in the US

Obstructive Hypertrophic Cardiomyopathy (oHCM)
Bristol-Myers Squibb362 enrolled1 locationNCT07557498
Recruiting
Phase 2Phase 3

A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).

PediatricSymptomatic Obstructive Hypertrophic Cardiomyopathy
Cytokinetics55 enrolled38 locationsNCT06412666
Recruiting
Phase 2

Ademetionine in Obstructive Hypertrophic Cardiomyopathy

Obstructive Hypertrophic Cardiomyopathy (oHCM)
China National Center for Cardiovascular Diseases44 enrolled3 locationsNCT07367724
Recruiting
Phase 4

A Study of Mavacamten in Adults With Obstructive Hypertrophic Cardiomyopathy in India (ROVER)

Symptomatic Obstructive Hypertrophic Cardiomyopathy
Bristol-Myers Squibb50 enrolled31 locationsNCT07004972
Recruiting
Phase 3

A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy

Non-obstructive Hypertrophic CardiomyopathyObstructive Cardiomyopathy, Hypertrophic
Lexicon Pharmaceuticals500 enrolled107 locationsNCT06481891
Recruiting

Mavacamten Post-marketing Surveillance in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan

Obstructive Hypertrophic Cardiomyopathy (oHCM)
Bristol-Myers Squibb200 enrolled1 locationNCT07383025
Recruiting

A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)

Obstructive Hypertrophic Cardiomyopathy
Bristol-Myers Squibb1,600 enrolled99 locationsNCT05489705
Recruiting
Phase 3

A Phase III Trial of HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy

Obstructive Hypertrophic Cardiomyopathy
Shandong Suncadia Medicine Co., Ltd.216 enrolled1 locationNCT07021976
Recruiting
Phase 4

Treatment Effects of Bisoprolol and Verapamil in Symptomatic Patients With Non-obstructive Hypertrophic Cardiomyopathy

Non-obstructive Hypertrophic Cardiomyopathy
Morten Steen Kvistholm Jensen100 enrolled4 locationsNCT05569382
Recruiting
Phase 2

A Phase II Clinical Study of HRS-1893 in Non-obstructive Hypertrophic Cardiomyopathy

Non-obstructive Hypertrophic Cardiomyopathy
Shandong Suncadia Medicine Co., Ltd.84 enrolled1 locationNCT06816251
Recruiting
Phase 4

ENavogliflozin DElivering Alleviation of Ventricular Diastolic Dysfunction in nonObstRuctive Hypertrophic CardioMyopathy

Nonobstructive Hypertrophic Cardiomyopathy
Yonsei University200 enrolled1 locationNCT06580717
Recruiting

Real-world Patient Reported Outcomes Among Patients Treated With Camzyos

Obstructive Hypertrophic Cardiomyopathy
Bristol-Myers Squibb118 enrolled1 locationNCT06551129
Recruiting

A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Obstructive Hypertrophic Cardiomyopathy
Bristol-Myers Squibb600 enrolled2 locationsNCT06146660
Recruiting

Effect of Mavacamten Treatment on Coronary Flow Reserve in oHCM

Obstructive Hypertrophic Cardiomyopathy
Michael Ayers20 enrolled1 locationNCT06023186